Serum Institute CEO Adar Poonawalla plans vaccine production outside India: Report

Serum Institute CEO Adar Poonawalla plans vaccine production outside India: Report

FPJ Web DeskUpdated: Saturday, May 01, 2021, 02:15 PM IST
article-image
SII CEO Adar Poonawalla | Twitter/ @adarpoonawalla

With the surge in coronavirus cases and deaths in India, Pune-based Serum Institute of India (SII) is struggling to meet supplies. CEO Adar Poonawalla told Times of India on Friday that the firm is planning to begin vaccine production outside India. Poonawalla said, ‘there's going to be an announcement in the next few days”.

The SII, which is India's largest vaccine manufacturer and the world’s by volume, manufactures the AstraZeneca COVID-19 vaccine jointly developed with Oxford University. It is sold in India under the name Covishield. "

The SII would be able to increase its monthly vaccine production to 100 million doses by July this year, Poonawalla said. It would raise its production capacity from 2.5 billion to 3 billion doses a year within six months, he was quoted as saying in TOI.

The nation's coronavirus cases may peak between May 3-5, according to scientists advising the government.

RECENT STORIES

Exciting Investment Opportunities Are Available, In The Capital Market

Exciting Investment Opportunities Are Available, In The Capital Market

Coromandel International Q4 Profit Falls 33% To ₹164 Cr On Lower Income

Coromandel International Q4 Profit Falls 33% To ₹164 Cr On Lower Income

PM SVANidhi: Centre Paid ₹147.82 Crore In Interest Subsidy On Loans

PM SVANidhi: Centre Paid ₹147.82 Crore In Interest Subsidy On Loans

'It Levels The Playing Field': After Old Video, Nikhil Kamath's Article Supporting Inheritance Tax...

'It Levels The Playing Field': After Old Video, Nikhil Kamath's Article Supporting Inheritance Tax...

Rupee On The Rise: Expert Forecasts Appreciation To ₹82-82.50 In FY25

Rupee On The Rise: Expert Forecasts Appreciation To ₹82-82.50 In FY25